CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy

by Weerawat Manosuthi, Chonlaphat Sukasem, Aroon Lueangniyomkul, Wiroj Mankatitham, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi, Somnuek Sungkanuparph
Published 2018

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients

by Weerawat Manosuthi, Chonlaphat Sukasem, Aroon Lueangniyomkul, Wiroj Mankatitham, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi, Somnuek Sungkanuparph
Published 2018

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens

by Weerawat Manosuthi, Wiroj Mankatitham, Aroon Lueangniyomkul, Wisit Prasithsirikul, Preecha Tantanathip, Busakorn Suntisuklappon, Anongnuch Narkksoksung, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/μL

by Weerawat Manosuthi, Somnuek Sungkanuparph, Somsit Tansuphaswadikul, Suthat Chottanapund, Wiroj Mankatitham, Sukanya Chimsuntorn, Chayanan Sittibusaya, Visal Moolasart, Achara Chaovavanich
Published 2018

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study

by Weerawat Manosuthi, Aroon Lueangniyomkul, Wiroj Mankatitham, Sukanya Chimsuntorn, Preecha Tantanathip, Supeda Thongyen, Busakorn Suntisuklappon, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study

by Weerawat Manosuthi, Wiroj Mankatitham, Aroon Lueangniyomkul, Supeda Thongyen, Sirirat Likanonsakul, Pawita Suwanvattana, Unchana Thawornwan, Busakorn Suntisuklappon, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifa...

by Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip, Wiroj Mankatitham, Aroon Lueangniyomkul, Supeda Thongyen, Boonchuay Eampokarap, Sumonmal Uttayamakul, Pawita Suwanvattana, Samroui Kaewsaard, Kiat Ruxrungtham
Published 2018

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in hiv-infected patients receiving rif...

by Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip, Aroon Lueangniyomkul, Wiroj Mankatitham, Wisit Prasithsirskul, Sunantha Burapatarawong, Supeda Thongyen, Sirirat Likanonsakul, Unchana Thawornwa, Vilaiwan Prommool, Kiat Ruxrungtham
Published 2018

Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome

by Weerawat Manosuthi, Hong Van Tieu, Wiroj Mankatitham, Aroon Lueangniyomkul, Jintanat Ananworanich, Anchalee Avihingsanon, Umaporn Siangphoe, Sukonsri Klongugkara, Sirirat Likanonsakul, Unchana Thawornwan, Bussakorn Suntisuklappon, Somnuek Sungkanuparph
Published 2018

Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/μL

by Weerawat Manosuthi, Somnuek Sungkanuparph, Somsit Tansuphaswadikul, Yaowarat Inthong, Wisit Prasithsirikul, Suthat Chottanapund, Wiroj Mankatitham, Sukanya Chimsuntorn, Chayanan Sittibusaya, Visal Moolasart, Nopphanath Chumpathat, Patamavadee Termvises, Achara Chaovavanich
Published 2018